WallStreetZenWallStreetZen

NASDAQ: AZN
Astrazeneca PLC Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Astrazeneca earnings were $6.5B for the trailing 12 months ending Sep 30, 2024, with 10% growth year over year. The latest AZN earnings report on Sep 30, 2024 announced Q3 2024 earnings of $1.4B, down 25.8% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, AZN reported annual earnings of $6.0B, with 81.1% growth. The next AZN earnings date is Feb 6, 2025.

AZN past earnings growth

How has AZN's earnings growth performed historically?

Company
10%
Industry
19.64%
Market
48.77%
AZN's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
AZN's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
AZN's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

AZN earnings history

Current Revenue
$51.2B
Current Earnings
$6.5B
Current Profit Margin
12.7%
AZN's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

AZN Return on Equity

Current Company
16.6%
Current Industry
40.9%
Current Market
35%
AZN's Return on Equity (16.6%)... subscribe to Premium to read more.
High Return on Equity Performance

AZN Return on Assets

Current Company
6.3%
Current Industry
8.2%
AZN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when AZN announces earnings.

AZN Return on Capital Employed

Current Company
12.24%
Current Industry
13.9%
AZN has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

AZN vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
AZN$15.35B$6.50B+21.02%$2.09
NVSN/A$17.60B+10.92%$8.63
MRK$19.22B$12.15B+5.82%$4.79
AMGN$13.48B$4.23B-9.66%$7.89
PFE$10.74B$4.25B-23.60%$0.76
View Top General Drug Manufacturer Stocks

AZN earnings dates

Next earnings date
Feb 6, 2025

Astrazeneca Earnings Reports & History FAQ

What were Astrazeneca's earnings last quarter?

On AZN's earnings call on Invalid Date, Astrazeneca (NASDAQ: AZN) reported Q3 2024 earnings per share (EPS) of $0.46, up 3.37% year over year. Total AZN earnings for the quarter were $1.43 billion. In the same quarter last year, Astrazeneca's earnings per share (EPS) was $0.45.

If you're new to stock investing, here's how to buy Astrazeneca stock.

When does Astrazeneca report earnings?

The next AZN earnings date is Invalid Date. Add AZN to your watchlist to be reminded of Astrazeneca's next earnings date.

What was AZN's earnings growth in the past year?

As of Astrazeneca's earnings date in Invalid Date, Astrazeneca's earnings has grown 10% year over year. This is 9.64 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 19.64%. AZN earnings in the past year totalled $6.50 billion.

Is Astrazeneca profitable or losing money?

As of the last Astrazeneca earnings report, Astrazeneca is currently profitable. Astrazeneca's net profit (also called net income) for the twelve months ending Sep 30, 2024 was $6.50 billion, a 10.14% increase year over year.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.